Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Summary:
- Volatility is at a recent 2 week high. A high volatility of stock movement indicates uncertainty.
| MarketCap | 66.4M |
|---|---|
| PE Ratio | |
| PEG Ratio | |
| P/B | 3.5 |
| P/S (ttm) | |
| Earning Growth (QoQ) | |
| Revenue Growth (QoQ) | |
| Short % | 2% |
| Held by Institutions % | 42% |
| 1 Day Vol Adjusted Return | 0.7 |
| 1 Month Vol Adjusted Return | 0.1 |
| 3 Month Vol Adjusted Return | 4.3 |
| 6 Month Vol Adjusted Return | 3.4 |
| 20 Days SMA Price ZScore | -1.0 |
| 50 Days SMA Price ZScore | 0.3 |
| 12 -26 Days PPO | 0.6 |
| 1 Month Average Short Volume Ratio | 38.8 |
| 1 Day Volume Change ZScore | -1.9 |
| 1 Month Daily Vol | 5.4 |
Stock news
NEWTON, Mass., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that company management will participate in two upcoming investor conferences in March: Cowen’s 41st Annual Health Care Conference Louis Brenner, M.D., Allena’s President and Chief Executive Offi...
A look at the shareholders of Allena Pharmaceuticals, Inc. ( NASDAQ:ALNA ) can tell us which group is most powerful...
-- Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) --NEWTON, Mass., Feb. 02, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced the appointment of Richard D. Katz, M.D., as Chief Financial Officer (CFO), effective immediately. Dr. Katz succeeds Edward W...
Allena Pharmaceuticals, Inc. (ALNA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
Is (ALNA) Outperforming Other Medical Stocks This Year?
NEWTON, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that company management will participate in two upcoming investor conferences in January: H.C. Wainwright Bioconnect 2021 Conference * Louis Brenner, M.D., Allena’s President and Chief Executi...
NEWTON, Mass., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, announced today that, due to demand, the underwriter has agreed to increase the size of the previously announced public offering and purchase on a firm commitment basis 10,400,000 shares of common stock of the ...
NEWTON, Mass., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, announced today that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC under which the underwriter has agreed to purchase on a firm commitment basis 8,000,000 shares of common stock ...